arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Sarepta Therapeutics, Inc.

SRPT
$17.54 ▼ -1.46 (-7.68%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
19 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
25
Health
Poor
Moderately Bearish
auto_awesome

Analytical Summary

Sarepta Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). On the positive side, Debt to Equity remains strong. Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $1.8B
Dividend Yield —
Revenue Growth 15.6% ↘
Op. Margin -31.8% ↘
ROIC -55.5% ↘
FCF / Share $-3.07 ↗
Trailing P/E —
Price / Book 1.6x
FCF Yield —
Debt / Equity 0.12
info Valuation on last close. End-of-day price, Nov 5, 2026.

19-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$2.20B
↑ +15.6% —
Net Income Profit after all expenses
$-713.41M
↓ -403.3% —
Operating Margin Operating profit as % of sales
-31.8%
↓ -377.6% 7th
FCF / Share Free cash flow per share
$-3.07
↑ +14.8% —
Long-Term Debt Long-term obligations
$140.50M
↓ -87.6% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
8
Returns ↓
14
Financial Health ↓
52
Cash Quality ↓
37

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 19 years · 70 quarters